Healing acceleration of repaired meniscus by synovial stem cells "Clinical study to assess the safety and efficacy of transplantation of autologous synovial mesenchymal stem cells in patients with knee meniscal tear"

Healing acceleration of repaired meniscus by synovial stem cells "Clinical study to assess the safety and efficacy of transplantation of autologous synovial mesenchymal stem cells in patients with knee meniscal tear" - Healing acceleration of repaired meniscus by synovial stem cells

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011881

Enrollment

Registered

2013-10-01

Start date

2013-10-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee meniscal tear

Interventions

meniscal repair and transplantation of autologous synovial stem cells to the sutured meniscus

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Meniscal tear such as radial tear, horizonal flap tear, complex tear and degenerative tear to which meniscal resection is generally applied 2) Patients with clinical symptoms such as knee joint unstability, limitation in range of motion, hydrathrosis and pain 3) Patients approved for treatment with surgery 4) Patients to whom meniscal repair is technically possible 5) Patients older than 20 years on the acquisition date of informed consent before clinical study 6) Patients who gave a written informed consent

Exclusion criteria

Exclusion criteria: 1) Patients who didn't give a written informed consent 2) Patients with active infection 3) Patients positive for HIV (HIV-1, HIV-2), HBV, HCV, or HTLV-1 4) Patients with active malignant tumors 5) Patients with sensitivity to antibiotic 6) Pregnant or breast-feeding women 7) Patients with diabetes 8) Patients in bad general condition 9) Patients evaluated as a contraindication to the clinical study by one's doctor

Design outcomes

Primary

Measure	Time frame
Safety of clinical research is evaluated on the presence, severity and frequency of adverse events caused by autologous synovial stem cells.	—

Secondary

Measure	Time frame
1) Feasibility of the quality control of cultured synovial stem cells 2) Subjective symptom (KOOS and NRS scores based on patient-oriented evaluation) and knee symptom before and after 4, 6, 12, 24 weeks of meniscal repair. 3) MRI assessment of sutured meniscus before and after 12, 24 weeks of meniscal repair 4) Width of joint space evaluated by X-ray examination before and after 12, 24 weeks of meniscal repair	—

Measure

Time frame

1) Feasibility of the quality control of cultured synovial stem cells 2) Subjective symptom (KOOS and NRS scores based on patient-oriented evaluation) and knee symptom before and after 4, 6, 12, 24 weeks of meniscal repair. 3) MRI assessment of sutured meniscus before and after 12, 24 weeks of meniscal repair 4) Width of joint space evaluated by X-ray examination before and after 12, 24 weeks of meniscal repair

—

Countries

Japan

Contacts

Public Contactoffice administrator

Medical Hospital of Tokyo Medical and Dental University Clinical Research Center

tiken.crc@tmd.ac.jp03-5803-5612

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Healing acceleration of repaired meniscus by synovial stem cells &quot;Clinical study to assess the safety and efficacy of transplantation of autologous synovial mesenchymal stem cells in patients with knee meniscal tear&quot;